filmov
tv
Algernon Pharmaceuticals' breakthrough approach to stroke and TBI recovery
Показать описание
Christopher Moreau, CEO of Algernon Pharmaceuticals Inc. (CSE: AGN | OTCQB: AGNPF | FSE: AGW0), discusses the company’s sale of Ifenprodil to Seyltx, and their current focus on DMT as a treatment for stroke and traumatic brain injury.
Algernon Pharmaceuticals is a clinical-stage, Canadian drug development and repurposing company investigating drugs and naturally occurring compounds for unmet global medical needs.
Engage with Market One
Algernon Pharmaceuticals is a clinical-stage, Canadian drug development and repurposing company investigating drugs and naturally occurring compounds for unmet global medical needs.
Engage with Market One
0:08:16
0:04:33
0:04:21
0:45:24
0:04:50
0:05:53
0:58:11
0:30:31
0:19:40
0:06:06
0:01:34
0:25:54
0:12:43
0:26:00
0:09:49
0:28:53
0:05:10
0:26:46
0:17:00
0:51:09
0:59:44
0:53:50
0:11:36
0:44:43